The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).
Acute exacerbation of COPD (AECOPD)are usual and frequent cause of admission in emergency room (ER). No validated clinical or biological predictor of evolution are available. The main objective is to determine the prognosis value of Mr proADM in addition to the clinical risk stratification for AE COPD patients in ER. Patients presenting with a AECOPD diagnosis in ER will have a blood sample collected and freezed at their admission. Mr proADM will be assessed at the end of the study. Clinicians in charge of patients will not have the result during the management of their patients. This study implies no change in the patients' management. Data related to the patients'demographic,current exacerbation and basic COPD characteristics will be collected.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
370
Hôpital Lariboisière
Paris, Paris, France
Pitié Salpétrière Hospital
Paris, Paris, France
composite outcome measure
Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER
Time frame: at Day 30
composite outcome
Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER
Time frame: at Day 7 of ER admission
correlation between Mr proADM and patients Severity
Correlation between MR proADM and patient's severity
Time frame: at Day 7 and Day 30 of ED admission
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.